Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-4,6-13C2-1,3,5-15N3-2-carboxylic acid, monopotassium salt, hydrate
Purity: ≥95%
Formula Markup: C2[13C]2H2[15N]3O4 / K [XH2O]
Formula Weight: 200.1
Notes: Oxonic acid-13C2,15N3 is intended for use as an internal standard for the quantification of oxonic acid (potassium salt) (Item No. 22586) by GC- or LC-MS. Oxonic acid is a uricase inhibitor (IC50 = 0.8 µM) that prevents metabolism and excretion of uric acid.{58362,40118} It also inhibits orotate phosphoribosyltransferase (ORPT), reducing OPRT-mediated phosphorylation of 5-fluorouracil (5-FU; Item No. 14416) in Yoshida sarcoma cell extracts with an IC50 value of 3.7 µM.{58363} Oxonic acid (10-50 mg/kg) decreases the severity of gastrointestinal tract injury and the incidence of diarrhea induced by the 5-FU prodrug tegafur (Item No. 26076) and uracil (Item No. 26088) without loss of antitumor activity in a rat Yoshida sarcoma model. It has also been used to induce hyperuricemia in rodents.{58364} Formulations containing oxonic acid have been used in the treatment of head, neck, lung, pancreatic, gastric, and breast carcinomas.
English
Deutsch
